173 related articles for article (PubMed ID: 25144632)
1. Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.
Tan TM; Salem V; Troke RC; Alsafi A; Field BC; De Silva A; Misra S; Baynes KC; Donaldson M; Minnion J; Ghatei MA; Godsland IF; Bloom SR
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2317-24. PubMed ID: 25144632
[TBL] [Abstract][Full Text] [Related]
2. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
[TBL] [Abstract][Full Text] [Related]
3. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.
Parker JC; Lavery KS; Irwin N; Green BD; Greer B; Harriott P; O'Harte FP; Gault VA; Flatt PR
J Endocrinol; 2006 Oct; 191(1):93-100. PubMed ID: 17065392
[TBL] [Abstract][Full Text] [Related]
4. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
5. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects.
Fernández-García JC; Murri M; Coin-Aragüez L; Alcaide J; El Bekay R; Tinahones FJ
Clin Endocrinol (Oxf); 2014 May; 80(5):671-6. PubMed ID: 23573808
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.
Wettergren A; Petersen H; Orskov C; Christiansen J; Sheikh SP; Holst JJ
Scand J Gastroenterol; 1994 Jun; 29(6):501-5. PubMed ID: 7915853
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.
Fung LC; Chisholm C; Greenberg GR
Endocrinology; 1998 Jan; 139(1):189-94. PubMed ID: 9421414
[TBL] [Abstract][Full Text] [Related]
9. Comparison of glucostatic parameters after hypocaloric diet or bariatric surgery and equivalent weight loss.
Plum L; Ahmed L; Febres G; Bessler M; Inabnet W; Kunreuther E; McMahon DJ; Korner J
Obesity (Silver Spring); 2011 Nov; 19(11):2149-57. PubMed ID: 21593800
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio DA; Kahn SE; Leusner CR; Ensinck JW
J Clin Invest; 1994 May; 93(5):2263-6. PubMed ID: 8182159
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man.
Wettergren A; Maina P; Boesby S; Holst JJ
Scand J Gastroenterol; 1997 Jun; 32(6):552-5. PubMed ID: 9200286
[TBL] [Abstract][Full Text] [Related]
12. Peptide YY is secreted after oral glucose administration in a gender-specific manner.
Kim BJ; Carlson OD; Jang HJ; Elahi D; Berry C; Egan JM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6665-71. PubMed ID: 16174724
[TBL] [Abstract][Full Text] [Related]
13. First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis.
Basso N; Capoccia D; Rizzello M; Abbatini F; Mariani P; Maglio C; Coccia F; Borgonuovo G; De Luca ML; Asprino R; Alessandri G; Casella G; Leonetti F
Surg Endosc; 2011 Nov; 25(11):3540-50. PubMed ID: 21638183
[TBL] [Abstract][Full Text] [Related]
14. Circulating concentrations of glucagon-like peptide 1, glucose-dependent insulinotropic peptide, peptide YY, and insulin in client-owned lean, overweight, and diabetic cats.
McMillan CJ; Zapata RC; Chelikani PK; Snead EC; Cosford K
Domest Anim Endocrinol; 2016 Jan; 54():85-94. PubMed ID: 26609567
[TBL] [Abstract][Full Text] [Related]
15. Peptide YY3-36 and glucagon-like peptide-1 in functional dyspepsia. Secretion and role in symptom generation.
Witte AB; Hilsted L; Holst JJ; Schmidt PT
Scand J Gastroenterol; 2016; 51(4):400-9. PubMed ID: 26503455
[TBL] [Abstract][Full Text] [Related]
16. Does GLP-1 suppress its own basal secretion?
Elahi D; Ruff DA; Carlson OD; Meneilly GS; Habener JF; Egan JM
Endocr Res; 2016; 41(1):16-20. PubMed ID: 26186406
[TBL] [Abstract][Full Text] [Related]
17. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects.
Jacobsen SH; Olesen SC; Dirksen C; Jørgensen NB; Bojsen-Møller KN; Kielgast U; Worm D; Almdal T; Naver LS; Hvolris LE; Rehfeld JF; Wulff BS; Clausen TR; Hansen DL; Holst JJ; Madsbad S
Obes Surg; 2012 Jul; 22(7):1084-96. PubMed ID: 22359255
[TBL] [Abstract][Full Text] [Related]
18. Appetite-Regulating Hormones Are Reduced After Oral Sucrose vs Glucose: Influence of Obesity, Insulin Resistance, and Sex.
Yunker AG; Luo S; Jones S; Dorton HM; Alves JM; Angelo B; DeFendis A; Pickering TA; Monterosso JR; Page KA
J Clin Endocrinol Metab; 2021 Mar; 106(3):654-664. PubMed ID: 33300990
[TBL] [Abstract][Full Text] [Related]
19. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.
Vahl TP; Paty BW; Fuller BD; Prigeon RL; D'Alessio DA
J Clin Endocrinol Metab; 2003 Apr; 88(4):1772-9. PubMed ID: 12679472
[TBL] [Abstract][Full Text] [Related]
20. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
